Enliven Therapeutics (ELVN) Stock Price, News & Analysis

Company Overview

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers. Both programs are orally administered targeted therapies and are being evaluated through clinical development.

The company was founded in 2019 and is headquartered in Boulder, Colorado. As a development-stage biotechnology company, Enliven’s operations are primarily focused on research, clinical studies, regulatory activities, and advancing its oncology pipeline toward potential commercialization.

Key Stats

• Today's Range: $38.51 to $39.95
• 50-Day Range: $39.28 to $61.15
• 52-Week Range: $14.78 to $62.32
• Volume: 1.22 million shs
• Average Volume: 1.59 million shs
• Market Capitalization: $2.88 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $74.44
• Consensus Rating: Moderate Buy

Enliven Therapeutics Stock Analysis - MarketRank™

Enliven Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 523rd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enliven Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Enliven Therapeutics has a consensus price target of $74.44, representing about 89.5% upside from its current price of $39.28.

Amount of Analyst Coverage

Enliven Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.79) to ($2.29) per share.

Price to Book Value per Share Ratio

Enliven Therapeutics has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.57% of the float of Enliven Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Enliven Therapeutics has a short interest ratio ("days to cover") of 5.49.

Change versus previous month

Short interest in Enliven Therapeutics has recently increased by 20.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enliven Therapeutics does not currently pay a dividend.

Dividend Growth

Enliven Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.38

News Sentiment

Enliven Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Enliven Therapeutics this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for ELVN on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,140,085.00 in company stock.

Percentage Held by Insiders

3.00% of the stock of Enliven Therapeutics is held by insiders.

Percentage Held by Institutions

95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ELVN
• CIK: 1672619
• Web: www.enliventherapeutics.com
• Phone: (650) 547-5814
• Fax: N/A
• Employees: 67
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Enliven Therapeutics: $74.44
• High Price Target: $82.00
• Low Price Target: $64.00
• Potential Upside/Downside: +89.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$103.69 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -18.55%
• Return on Assets: -18.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 64.07
• Quick Ratio: 64.07

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.74 per share
• Price / Book: 5.07

Miscellaneous

• Outstanding Shares: 73,270,000
• Free Float: 71,073,000
• Market Cap: $2.88 billion
• Optionable: Optionable
• Beta: 0.24